Abstract
The tetravalent live attenuated dengue vaccine candidate TV003 induces neutralizing antibodies against all four dengue virus serotypes (DENV1–DENV4) and protects against experimental challenge with DENV2 in humans. Here, we track vaccine viremia and B and T cell responses to this vaccination/challenge model to understand how vaccine viremia links adaptive immunity and development of protective antibody responses. TV003 viremia triggers an acute plasmablast response that, in combination with DENV-specific CD4+ T cells, correlates with serum neutralizing antibodies. TV003 vaccinees develop DENV2-reactive memory B cells, including serotype-specific and multivalent specificities in line with the composition of serum antibodies. There is no post-challenge plasmablast response in vaccinees, although stronger and earlier post-TV003 plasmablast responses associate with sterile humoral protection from DENV2 challenge. TV003 vaccine triggers plasmablasts and memory B cells, which, with support from CD4+ T cells, functionally link early vaccine viremia and the serum antibody responses.
Original language | English (US) |
---|---|
Article number | 100155 |
Journal | Cell Reports Medicine |
Volume | 1 |
Issue number | 9 |
DOIs | |
State | Published - Dec 22 2020 |
Keywords
- CD4 T cells
- TV003
- dengue vaccine
- humoral immune response
- memory B cells
- neutralizing antibodies
- protective immunity
- serotype-specific antibodies
- tetravalent live attenuated vaccine
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology